​Is the double antibody necessarily better than the monoclonal antibody?

With the approval of the fourth dual-antibody drug in the world, the once "quiet" dual-antibody came to the eve of the outbreak, and the track was evaluated by industry experts as "it has begun to be crowded before it has officially entered the game

So are double antibodies really better than monoclonal antibodies?

The answer does not seem so sure

It is the common goal of doctors and pharmaceutical companies to have more drugs that can solve unmet clinical needs on the market

Of course, if it is for a disease area where there is no treatment plan at present, a single-arm test can also be accepted by the drug regulatory department under normal circumstances

01 Double anti-technology is ahead of science

In fact, in addition to double antibodies, both the third and fourth antibodies are in the research stage

The four antibodies most well-known in the industry are the two products of Baili Pharmaceutical, GNC-038 and GNC-039, both of which have entered the clinical stage

Zejing, code-named ZGGS001, is a trispecific antibody molecule that mainly inhibits tumor immunity and multiple tumor angiogenesis pathways, and regulates the tumor microenvironment

There is a view that the current industry research on double antibodies and even polyclonal antibodies is that "technology is ahead of science

Polyclonal combination has been able to achieve a technological breakthrough, but whether it will produce a 1+1>2 effect, whether it can be safe enough, and the toxicity is not increased, is still being explored

Answering these questions requires a basic knowledge: how much do you know about the disease?

Two separate and effective antibodies, combined together, some increase the efficacy, while others will bring side effects and increase toxicity.

02 Drug resistance and safety are the core

In fact, regardless of double antibodies or polyclonal antibodies, the core goals are two, one is to overcome the resistance of the original drugs, and the other is to improve the efficacy and solve the unmet clinical needs

Therefore, for the research and development of double-antibody drugs, it is necessary to return to the essence of science and the essence of drugs

The future is bright, and many pharmaceutical companies have already deployed in this field

However, one thing that needs to be clear is that after the industry has experienced the "backlash" of tinibs, PD-1/PD-L1, and the crowded ADC track, the development of double or multi-antibody drugs can be viewed more rationally: clinical Value is the core, it's not necessary to show off skills